Scientists in China have used a next-generation form of CRISPR genome-editing to repair a disease-causing mutation in human embryos, the first use of the technique in viable embryos that were created by a standard fertility clinic technique.

The study is a notable advance over previous attempts to edit human embryos and brings closer the day when genome editing might be used to alter the DNA of early-stage IVF embryos in such a way that the changes would be inherited by subsequent generations, potentially wiping out diseases caused by single genetic mutations.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy